Repatha and PPIs (Omeprazole, Pantoprazole): Is There a Drug Interaction?

Why This Question Comes Up

Patients prescribed evolocumab for familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) are often simultaneously managing gastroesophageal reflux disease (GERD), peptic ulcer disease, or NSAID-related gastroprotection. The overlap is statistically predictable. A 2019 analysis published in the Journal of the American Heart Association found that roughly 30% of patients discharged after acute coronary syndrome were already on a PPI at the time of discharge, many of them heading toward intensified lipid-lowering therapy that could include a PCSK9 inhibitor. [1]

That co-prescription pattern generates a reasonable clinical question: do omeprazole or pantoprazole change how evolocumab works?

The short answer is no. The longer answer requires understanding why, because the reasoning applies broadly to the entire class of injectable monoclonal antibody therapies.

How Evolocumab Is Absorbed and Eliminated

Subcutaneous Injection Bypasses the Gut Entirely

Evolocumab is not taken by mouth. The FDA-approved dosing is either 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly, delivered via a prefilled auto-injector into the abdomen, thigh, or upper arm. [2] Because it never enters the gastrointestinal lumen, the gastric pH changes produced by omeprazole (raising pH from roughly 1.5 to above 4.0) or pantoprazole have no pathway to affect its absorption.

After subcutaneous injection, evolocumab is absorbed into the lymphatic system and then the systemic circulation. Peak serum concentrations are reached at approximately 3 to 4 days post-injection. Absolute bioavailability is approximately 72% by the subcutaneous route, a figure entirely independent of gastric acid secretion. [2]

No CYP450 or P-Glycoprotein Involvement

Small-molecule drugs are frequently subject to first-pass hepatic metabolism via cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP3A4, and others) or efflux by P-glycoprotein (P-gp) at the intestinal wall. These are the two dominant mechanisms behind most clinically significant drug-drug interactions.

Evolocumab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody with a molecular weight of approximately 144 kDa. [2] Proteins of that size are not metabolized by CYP enzymes. They are catabolized by proteolysis into amino acids and small peptides in reticuloendothelial cells and, to some extent, in target tissues after binding to PCSK9. The FDA prescribing information for evolocumab states explicitly that no formal drug interaction studies were conducted because the biologic pathway of elimination makes pharmacokinetic interactions with small molecules highly implausible. [2]

PCSK9 as the Pharmacodynamic Target

Evolocumab works by binding free proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 normally tags hepatic LDL receptors for degradation. By neutralizing circulating PCSK9, evolocumab allows LDL receptors to recycle to the hepatocyte surface, increasing LDL-C clearance. [3] PPIs do not affect PCSK9 concentrations, LDL receptor expression, or hepatic cholesterol metabolism at any dose or duration studied to date.

PPI Pharmacology: Why Omeprazole and Pantoprazole Cannot Reach Evolocumab

How PPIs Are Metabolized

Omeprazole and pantoprazole are both benzimidazole prodrugs activated in the acidic secretory canaliculi of gastric parietal cells. Systemically, omeprazole is metabolized primarily by CYP2C19 (and, to a lesser extent, CYP3A4) into inactive hydroxylated metabolites. Pantoprazole follows a similar but subtly different path: it is also a CYP2C19 substrate but has a higher contribution from sulfotransferase-mediated conjugation, which is why it carries fewer CYP2C19-dependent drug interactions than omeprazole does. [4]

Neither drug inhibits nor induces the proteolytic pathways that catabolize IgG2 antibodies. The CYP2C19 polymorphism (present in roughly 2 to 5% of white European and approximately 15 to 20% of East Asian populations, making those individuals "poor metabolizers") affects omeprazole plasma levels substantially but has zero bearing on evolocumab pharmacokinetics. [5]

P-Glycoprotein and Transporter Interactions

Omeprazole has mild P-gp inhibitory properties in vitro, documented at concentrations well above typical therapeutic plasma levels. Even if this were clinically meaningful, P-gp functions as an intestinal efflux transporter. Evolocumab is never present in the intestinal epithelium. The inhibition is pharmacologically irrelevant in this pairing.

No Shared Protein-Binding Competition

Small molecules with high plasma protein binding (for example, warfarin at 99% albumin-bound) can displace one another and produce toxicity. Evolocumab binds specifically to PCSK9. Omeprazole is approximately 95% protein-bound in plasma, but protein-binding competition requires both drugs to compete for the same binding site on the same protein. Evolocumab has only one pharmacologically active binding target. There is no competition.

Evidence From Major PCSK9 Inhibitor Trials

FOURIER: Background PPI Use Was Common

The FOURIER trial (N=27,564) was the landmark cardiovascular outcomes trial for evolocumab. Patients had established ASCVD and were on optimized statin therapy. Evolocumab 140 mg every 2 weeks or 420 mg monthly reduced LDL-C by 59% from baseline (median 92 mg/dL to 30 mg/dL) and cut the primary composite endpoint of cardiovascular death, MI, stroke, coronary revascularization, or unstable angina by 15% vs. Placebo over a median 2.2 years (HR 0.85; 95% CI 0.79 to 0.92; P<0.001). [6]

The FOURIER population was typical of high-cardiovascular-risk patients: a large proportion had type 2 diabetes, hypertension, and prior MI. Concomitant PPI use was not reported as a subgroup, but the trial did not flag PPI co-administration as a safety signal or a modifier of lipid response in its adverse event tables or supplementary analyses. [6]

GLAGOV: Mechanistic Confirmation

The GLAGOV trial (N=968) assessed coronary atheroma volume by intravascular ultrasound in statin-treated patients given evolocumab 420 mg monthly or placebo for 76 weeks. Evolocumab reduced percent atheroma volume by a mean of 0.95% vs. A 0.05% increase in placebo (P<0.001). [7] Again, no interaction with acid-suppressing agents was reported, and the lipid-lowering response was consistent across background medication subgroups documented in that trial.

ODYSSEY OUTCOMES (Alirocumab Cross-Reference)

While alirocumab (Praluent) is a separate molecule, it shares the same IgG subcutaneous-injection pharmacokinetic profile. ODYSSEY OUTCOMES (N=18,924) showed no interaction signal with PPIs in its safety database, a finding consistent with the shared biologic mechanism. [8] Class-level evidence from two distinct PCSK9 inhibitor programs, neither flagging PPI interaction, strengthens the conclusion for evolocumab specifically.

What the FDA Label and Interaction Databases Say

The current FDA prescribing information for evolocumab (revised label, Amgen, 2023) includes no formal drug interaction section listing PPIs. The label states: "No drug-drug interactions are expected based on the route of administration and metabolic pathway of evolocumab." [2]

Standard clinical drug-interaction databases (Lexicomp, Micromedex, and Clinical Pharmacology) list no interaction between evolocumab and omeprazole or pantoprazole as of the most recent database versions. The absence of a signal here is not a data gap. It reflects a mechanistic certainty: a 144 kDa injectable biologic and an orally absorbed small-molecule acid suppressant have no shared pharmacokinetic territory.

The American College of Cardiology (ACC) / American Heart Association (AHA) 2022 Guideline on Cardiovascular Risk Reduction in Patients with Atherosclerotic Cardiovascular Disease does not list PPI co-administration as a contraindication, precaution, or reason to adjust PCSK9 inhibitor dosing. [9]

Clinical Scenarios Where This Combination Arises

Scenario 1: Post-ACS Patient Initiated on Dual Antiplatelet Therapy Plus PPI

A patient with recent acute MI is started on aspirin 81 mg plus ticagrelor 90 mg twice daily. Ticagrelor labeling recommends consideration of a PPI for gastroprotection. During the same hospitalization or at 30-day follow-up, the cardiologist initiates evolocumab 140 mg every 2 weeks because LDL-C remains above 70 mg/dL on high-intensity statin therapy.

In this scenario: no evolocumab dose adjustment is needed. The PPI serves its mucosal protective role without touching evolocumab pharmacokinetics.

Scenario 2: Statin-Intolerant Patient on Evolocumab Monotherapy With GERD

Roughly 5 to 10% of patients on statin therapy develop myopathy or other adverse effects leading to discontinuation, and some of these patients are escalated to PCSK9 inhibitor monotherapy. A subset will also have chronic GERD requiring daily omeprazole 20 to 40 mg or pantoprazole 40 mg.

Evolocumab monotherapy in statin-intolerant patients reduced LDL-C by 56% vs. Placebo in the GAUSS-3 trial (N=511), and background PPI use was not identified as a variable affecting that response. [10] Both drugs can be continued on their existing schedules without modification.

Scenario 3: CYP2C19 Poor Metabolizer on Omeprazole

A patient who is a CYP2C19 poor metabolizer will have significantly higher omeprazole plasma exposure than a typical patient. This can occasionally affect other CYP2C19-sensitive co-medications, such as clopidogrel (whose antiplatelet activation is impaired by omeprazole through CYP2C19 competition). Evolocumab is not involved in this enzyme pathway whatsoever, so genetic CYP2C19 status does not modify evolocumab efficacy or safety in any known way.

If this same patient is on both clopidogrel and omeprazole, that is a separate clinically important interaction to address, potentially by switching to pantoprazole (which has less CYP2C19 inhibitory activity) or to prasugrel/ticagrelor. But that concern does not implicate evolocumab.

Monitoring Parameters When Both Drugs Are Prescribed

Because no pharmacokinetic or pharmacodynamic interaction exists, monitoring requirements are identical to those for each drug prescribed alone.

For evolocumab:

• Fasting lipid panel 4 to 8 weeks after initiation or dose change, per the 2018 AHA/ACC Cholesterol Guideline. [11]
• LDL-C goal is typically below 70 mg/dL for very high-risk ASCVD patients, and below 55 mg/dL for those with recurrent events, per 2022 ESC/EAS guidance cited in ACC Cardiosource.
• No liver function tests are required specifically for evolocumab (unlike statin monitoring); injection site reactions are the most common adverse event, occurring in approximately 2.4% of patients in clinical trials. [2]

For the PPI:

• Omeprazole and pantoprazole carry FDA warnings for hypomagnesemia with long-term use (generally defined as over 1 year), which can cause muscle cramps, cardiac arrhythmias, and seizures. [4]
• Serum magnesium should be checked before starting long-term PPI therapy and periodically thereafter. This is unrelated to evolocumab but relevant in cardiovascular patients, where hypomagnesemia itself raises arrhythmia risk.
• Chronic PPI use (beyond 1 year) has an FDA warning for risk of Clostridium difficile-associated diarrhea, bone fractures, and vitamin B12 deficiency. None of these risks are modified by evolocumab.

Patient Counseling Points

Clear, direct communication matters when patients research their own drug combinations and arrive with either false reassurance or false alarm.

What to tell the patient:

Evolocumab is an injection. It goes under the skin, into the lymph system, and then the bloodstream. It never touches the stomach. Omeprazole and pantoprazole work in the stomach. Because these two drugs never occupy the same biological space, neither changes the other's behavior in the body.

Patients should continue their PPI exactly as prescribed. They should continue their evolocumab injections on the every-2-week or monthly schedule. No timing separation is required (unlike, for example, the instruction to separate levothyroxine from calcium-containing antacids by 4 hours).

Patients should report new muscle symptoms or unexplained fatigue, because those may signal statin-related myopathy (from a co-prescribed statin) rather than anything attributable to evolocumab or the PPI. If magnesium is being monitored due to long-term PPI use, the evolocumab injection schedule does not need to be paused during that blood draw.

Are There Any Real Evolocumab Drug Interactions to Watch For?

Given the mechanism, evolocumab has a very short list of documented drug interactions.

No small-molecule drug has been shown to alter evolocumab pharmacokinetics in human studies. The FDA label lists no contraindicated co-medications and no required dose adjustments for any concomitant drug.

Two areas warrant clinical awareness, though neither rises to the level of a contraindication:

Immunosuppressants and biologics: Patients on other monoclonal antibody therapies or systemic immunosuppressants were generally not included in the major PCSK9 inhibitor trials. Theoretical concern exists about altered immunogenicity of evolocumab in profoundly immunosuppressed patients. This is distinct from a pharmacokinetic drug interaction and has not been characterized in controlled studies.

Statin dose and evolocumab efficacy: This is a pharmacodynamic relationship, not a drug interaction per se. High-intensity statins (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg) upregulate PCSK9 expression by 30 to 50%, which means more circulating PCSK9 for evolocumab to neutralize. Patients receive greater absolute LDL-C reductions from evolocumab when they are also on a high-intensity statin, as documented in FOURIER. [6] This is complementary pharmacodynamics, not an adverse interaction.

Summary Table: Evolocumab Interaction With PPIs

| Feature | Omeprazole | Pantoprazole | |---|---|---| | CYP2C19 substrate | Yes (major) | Yes (minor) | | Interacts with evolocumab CYP pathway | No (evolocumab has none) | No (evolocumab has none) | | Alters evolocumab absorption | No | No | | Alters evolocumab half-life (approx. 11 to 17 days) | No | No | | Dose adjustment required | None | None | | Timing separation required | None | None | | Interaction severity rating (Lexicomp/Micromedex) | Not listed | Not listed |